13F Holdings
中文EN

SXTC China SXT Pharmaceuticals, Inc. Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1723980 · Fiscal year ends 03/31

Financial factors as of 2026-03-31 (FY2026), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-34.6%
TTM net income YoY-87.8%
TTM EPS YoY97.4%
Revenue 3-yr CAGR-16.7%
Net income 3-yr CAGR—

Margins

Gross margin21.9%
Operating margin-625.9%
Net margin-545.2%
FCF margin—
EBITDA margin-619.4%

Returns

ROE-27.5%
ROA-22.0%
ROIC (approx.)—
Asset turnover0.04x

Leverage & solvency

Liabilities / assets14.5%
Debt / equity0.03x
Current ratio7.93x
Interest coverage-113.13x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue$1.14M$1.74M$1.93M$1.97M$2.60M
Cost of revenue$889,350$1.37M$1.37M$1.55M$1.35M
Gross profit$248,702$367,427$553,971$426,271$1.25M
R&D expense——$184,194$200,717$367,005
SG&A expense$7.13M$2.76M$2.64M$5.65M$5.52M
Operating income-$7.12M-$2.68M-$2.52M-$5.61M-$5.19M
Interest expense$62,965$648,221$544,279$476,776$36,695
Pretax income-$6.21M-$3.30M-$3.10M-$5.93M-$5.41M
Income tax————$328,146
Net income-$6.21M-$3.30M-$3.10M-$5.93M-$5.74M
EBITDA-$7.05M-$2.60M-$2.31M-$5.36M-$4.87M
EPS (basic)-9.13-348.17-4,285.66-177.84-137.92
EPS (diluted)-9.13-348.17-4,285.66-177.84-137.92
Weighted avg. shares (diluted)679,6489,48972333,37241,591
Banking
Loans, net———$38,358$11,404
Deposits—$7.27M———
Balance sheet
Cash & equivalents$28.18M$18.10M$12.08M$17.37M$15.57M
Receivables$931,567$1.30M$1.31M$1.34M$3.33M
Inventory$777,059$828,053$794,855$531,254$1.02M
Current assets$34.51M$21.30M$14.23M$19.52M$22.45M
PP&E, net$117,103$178,561$328,845$962,214$1.23M
Intangibles$6,328$11,808$19,101$27,868$38,762
Total assets$34.75M$21.66M$23.13M$29.55M$33.55M
Current liabilities$4.35M$6.01M$8.90M$14.50M$17.12M
Short-term debt$355,175$8,781$21,329$7,863$11,404
Long-term debt$644,390$96,264$117,129$117,862—
Total debt$999,565$105,045$138,458$125,725—
Total liabilities$5.05M$6.22M$9.20M$14.86M$17.12M
Shareholders' equity$29.71M$15.44M$13.93M$14.69M$16.08M
Net debt-$27.18M-$17.99M-$11.94M-$17.24M—
Shares outstanding—91,75613.76M457,3652.03M
Cash flow statement
Operating cash flow-$4.02M-$2.35M-$1.93M-$80,757$268,293
Capital expenditure—$2,023$7,063——
Free cash flow—-$2.35M-$1.94M——
Investing cash flow-$1.25M$63,516$26,423-$12,303-$46,909
Financing cash flow$14.43M$8.40M-$2.62M$2.94M$1.60M
Depreciation & amortization$73,668$82,297$203,247$250,162$320,007
Stock-based compensation$5.31M—$352,100$554,571$2.33M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.